Showing results (201-210 of 617) with videos related to
Sort By:
Pageof 62
Cancer Chemotherapy and Pharmacology|August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.Current Medical Research and Opinion|April 29, 2011
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trialsJames E Signorovitch, Eric Q Wu, Keith A Betts, et al.Theranostics|September 15, 2020
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine conceptsPeter Valent, Cem Akin, Karin Hartmann, et al.The Journal of Allergy and Clinical Immunology|June 21, 2020
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinionsPeter Valent, Cem Akin, Patrizia Bonadonna, et al.Journal of Geriatric Oncology|June 16, 2015
Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adultsK Rebecca Fega, Gregory A Abel, Gabriela Motyckova, et al.Oncotarget|March 10, 2016
Insulin receptor substrate 1 is a substrate of the Pim protein kinasesJin H Song, Sathish K R Padi, Libia A Luevano, et al.Blood Advances|September 8, 2021
A novel activating JAK1 mutation in chronic eosinophilic leukemiaWilliam Shomali, Alisa Damnernsawad, Talent Theparee, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2022
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical PracticePeter Valent, Karin Hartmann, Juliana Schwaab, et al.Blood Reviews|March 16, 2024
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?Geoffrey L Uy, Daniel J DeAngelo, Jay N Lozier, et al.Pageof 62